Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 4/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 4/20 | 0.43 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.42 |
| ▸ | IL1RN | P18510 | 1/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21457977 | 0.91 | CAPN1 (0.50) | MMP1MMP2MMP12MMP13LTA4H | |
| SCHEMBL21458073 | 0.83 | ANPEP (0.50) | MMP1MMP2MMP12MMP13MMP8 | |
| SCHEMBL3837984 | 0.83 | ANPEP (0.50) | MMP1MMP2MMP12MMP13MMP8 | |
| SCHEMBL21457982 | 0.79 | CAPN1 (0.62) | CTSK | |
| SCHEMBL4390231 | 0.79 | CAPN1 (0.62) | CTSK | |
| SCHEMBL5707491 | 0.77 | PSMB1 (0.47) | ANPEPLTA4H | |
| SCHEMBL15304656 | 0.77 | CAPN1 (0.53) | MMP1MMP2ANPEPMMP3 | |
| SCHEMBL21457988 | 0.76 | CAPN1 (0.64) | MMP1LTA4H | |
| SCHEMBL20880296 | 0.74 | CAPN1 (0.54) | SMN1; SMN2CTSK | |
| SCHEMBL13934277 | 0.73 | CAPN1 (0.47) | CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | OSAKA CITY UNIVERSITY (JP) | 2023-12-19 | — | — | US | disclosed |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | OSAKA CITY UNIVERSITY (JP) | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | PMP22, PRPH, NGF | MMP1 1253/4885MMP2 2186/4885MMP12 4622/4885 |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | PMP22, PRPH, NGF | MMP1 1253/4885MMP2 2186/4885MMP12 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.